Assessing Human Lung Pharmacokinetics Using Exhaled Breath Particles.

ABSTRACT: Background: It remains challenging to quantify lung pharmacokinetics (PK) of a drug administered and targeted to act in the lung. Exhaled breath particles (PEx), which are generated when collapsed distal airways reopen during inhalation, offer a noninvasive way to access undiluted epithelial lining fluid (ELF). Therefore, it was the aim of this study to investigate whether PK data can be derived from PEx. Methods: Six healthy volunteers received either an inhaled dose (400 µg) or an oral dose (8 mg) of salbutamol in a randomized, crossover design with 7-day washout between treatments. PEx were collected before and at nine time points after dosing (0-315 minutes [min]). Following each 15 min PEx sampling period, nasosorption and plasma samples were collected. Sal

SUBMITTER: Holz O 

PROVIDER: S-EPMC11844770 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature